ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07639
-0,08%
Bitcoin
63.762,26
-0,20%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Cardiff Oncology Inc (CRDF)

  7. Cardiff Oncology Inc (CRDF) News

CRDF

Cardiff Oncology (CRDF)

Cardiff Oncology Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CRDF
DatumZeitQuelleÜberschriftSymbolFirma
02/05/202422h05GlobeNewswire Inc.Cardiff Oncology Reports First Quarter 2024 Results and Provides Business UpdateNASDAQ:CRDFCardiff Oncology Inc
25/04/202422h05GlobeNewswire Inc.Cardiff Oncology to Report First Quarter 2024 Results and Provide Business UpdateNASDAQ:CRDFCardiff Oncology Inc
08/04/202422h05GlobeNewswire Inc.Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical StudyNASDAQ:CRDFCardiff Oncology Inc
08/03/202400h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRDFCardiff Oncology Inc
08/03/202400h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRDFCardiff Oncology Inc
08/03/202400h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRDFCardiff Oncology Inc
08/03/202400h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRDFCardiff Oncology Inc
06/03/202422h05GlobeNewswire Inc.Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024NASDAQ:CRDFCardiff Oncology Inc
29/02/202422h07GlobeNewswire Inc.Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateNASDAQ:CRDFCardiff Oncology Inc
29/02/202422h06GlobeNewswire Inc.Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRCNASDAQ:CRDFCardiff Oncology Inc
29/02/202422h05GlobeNewswire Inc.Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)NASDAQ:CRDFCardiff Oncology Inc
29/02/202422h00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CRDFCardiff Oncology Inc
26/02/202414h00GlobeNewswire Inc.Cardiff Oncology to Present at the Cowen 44th Annual Health Care ConferenceNASDAQ:CRDFCardiff Oncology Inc
22/02/202414h00GlobeNewswire Inc.Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business UpdateNASDAQ:CRDFCardiff Oncology Inc
06/02/202422h01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CRDFCardiff Oncology Inc
17/01/202416h30PR Newswire (US)Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer ResearchNASDAQ:CRDFCardiff Oncology Inc
08/01/202415h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRDFCardiff Oncology Inc
20/11/202322h05PR Newswire (US)Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:CRDFCardiff Oncology Inc
02/11/202321h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRDFCardiff Oncology Inc
02/11/202321h05PR Newswire (US)Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business UpdateNASDAQ:CRDFCardiff Oncology Inc
02/11/202321h02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRDFCardiff Oncology Inc
26/10/202322h05PR Newswire (US)Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business UpdateNASDAQ:CRDFCardiff Oncology Inc
26/09/202322h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRDFCardiff Oncology Inc
26/09/202322h05PR Newswire (US)Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib MonotherapyNASDAQ:CRDFCardiff Oncology Inc
05/09/202314h00PR Newswire (US)Cardiff Oncology to Present at Upcoming Investor Conferences in SeptemberNASDAQ:CRDFCardiff Oncology Inc
09/08/202322h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRDFCardiff Oncology Inc
09/08/202322h05PR Newswire (US)Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business UpdateNASDAQ:CRDFCardiff Oncology Inc
09/08/202322h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRDFCardiff Oncology Inc
07/08/202322h42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRDFCardiff Oncology Inc
07/08/202322h05PR Newswire (US)Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer RelationshipNASDAQ:CRDFCardiff Oncology Inc
 Showing the most relevant articles for your search:NASDAQ:CRDF

Kürzlich von Ihnen besucht

AMEX
XLF
Financial Select Sector
FX
EURUSD
Euro vs US Dollar
NASDAQ
AAPL
Apple
NYSE
MRK
Merck
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
NVDA
NVIDIA
USOTC
BNPQY
BNP Paribas (QX)
USOTC
RHHBY
Roche (QX)
FX
EURGBP
Euro vs Sterling
TG
BAYN
Bayer
NASDAQ
TSLA
Tesla
FX
EURJPY
Euro vs Yen
CCOM
US100
US Tech 100
TG
NOV
Novo Nordisk
AMEX
XLV
Health Care Select Sector
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten